Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, July 09, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) investors of a class action representing investors that bought securities between May 9, 2024 and May 8, 2025, inclusive (the "Class Period"). Iovance investors have until July 14, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F ...

Core Insights - The article emphasizes the importance of quantitative research, financial modeling, and risk management in equity valuation and market trends [1] - It highlights the experience of the analyst in leading teams for model validation and stress testing, showcasing a strong background in both fundamental and technical analysis [1] - The collaboration between the analyst and their research partner aims to provide high-quality, data-driven insights for investors [1] Company and Industry Analysis - The focus is on uncovering high-growth investment opportunities through rigorous risk management and a long-term perspective on value creation [1] - There is a particular interest in macroeconomic trends, corporate earnings, and financial statement analysis, which are crucial for providing actionable investment ideas [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Iovance Biotherapeutics, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 14, 2025, for a class action lawsuit [1][2] Group 1: Class Action Details - The class action lawsuit claims that Iovance made false and misleading statements regarding the effectiveness of new Authorized Treatment Centers (ATCs) in treating patients with Amtagvi, leading to higher costs and lower revenue [3] - Investors who purchased Iovance securities between May 9, 2024, and May 8, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [4] - The firm has been recognized for its achievements in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements since 2013 [4]

SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding Series A, Series B-1, Series C-1, Series D, Series E and Series F Warrants (the “Existing Warrants”) to purchase up to ...

Market Performance - U.S. stocks traded higher, with the Nasdaq Composite gaining over 100 points on Wednesday, while the Dow rose 0.18% to 44,319.31, the NASDAQ increased 0.62% to 20,545.29, and the S&P 500 climbed 0.31% to 6,245.11 [1] - Communication services shares increased by 1.1%, while consumer staples stocks dipped by 1% [1] Commodity News - Oil prices rose by 0.6% to $68.74, while gold prices fell by 0.1% to $3,315.70. Silver decreased by 0.4% to $36.610, and copper dropped by 3.8% to $5.4715 [5] European Market - European shares showed positive performance, with the eurozone's STOXX 600 rising 0.71%, Spain's IBEX 35 Index increasing by 1.07%, London's FTSE 100 gaining 0.13%, Germany's DAX 40 up by 1.32%, and France's CAC 40 rising by 1.40% [6] Asian Market - Asian markets closed mostly lower, with Japan's Nikkei gaining 0.33%, while Hong Kong's Hang Seng fell by 1.06%, China's Shanghai Composite declined by 0.13%, and India's BSE Sensex decreased by 0.21% [7] Company Developments - Calidi Biotherapeutics, Inc. saw its shares surge by 353% to $1.48 due to advancements in cancer treatment [9] - SU Group Holdings Limited's shares increased by 155% to $1.1609 after securing an HK$88.5 million hospital contract [9] - Evoke Pharma, Inc. shares rose by 171% to $7.20 following a notice of allowance for a U.S. patent application [9] - Bitmine Immersion Technologies, Inc. shares dropped by 47% to $59.22 after filing for a mixed shelf [9] - RxSight, Inc. shares fell by 42% to $7.39 after revising its 2025 revenue guidance downwards [9] - Vertical Aerospace Ltd. shares decreased by 31% to $4.77 after announcing a $60 million public offering at $5/share [9] Inventory Data - U.S. wholesale inventories declined by 0.3% month-over-month to $905.5 billion in May, aligning with preliminary estimates [11] - U.S. crude oil inventories increased by 7.070 million barrels in the week ended July 4, marking the largest gain since January [11]

Core Viewpoint - The article discusses the investigation by Monteverde & Associates PC into the acquisition of CARGO Therapeutics, Inc. by Concentra Biosciences, LLC, focusing on the fairness of the deal which includes a cash payment and contingent value rights for shareholders [1]. Group 1: Company Overview - CARGO Therapeutics, Inc. is being sold to Concentra Biosciences, LLC for $4.379 in cash per share, along with a non-transferable contingent value right [1]. - The contingent value right entitles shareholders to receive 100% of CARGO's closing net cash exceeding $217.5 million and 80% of net proceeds from the sale or licensing of specific CAR T therapies within two years post-closing [1]. Group 2: Legal Firm Background - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has a successful track record in recovering money for shareholders [1]. - The firm operates from the Empire State Building in New York City and specializes in class action securities litigation [2].

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive focuses on sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Points - Transgene has appointed Emmanuelle Quilès as an independent Director to its Board of Directors, succeeding Philippe Archinard, who is retiring [1][3] - Emmanuelle Quilès brings over 25 years of experience in strategic leadership roles within the global pharmaceutical industry, previously serving as Worldwide Vice President at Janssen Global Commercial Strategy Organization [2][5] - The appointment is effective from July 9, 2025, and Quilès will serve the remainder of Archinard's term until the 2026 Annual Shareholders' Meeting [3] Company Overview - Transgene is a biotechnology company focused on designing and developing virus-based immunotherapies for cancer treatment, with a portfolio that includes TG4050, TG4001, BT-001, and TG6050 [8] - The company utilizes its myvac® platform for individualized therapeutic vaccines and the Invir.IO® platform for multifunctional oncolytic viruses [9][10] - Transgene's clinical-stage programs are aimed at providing targeted immunotherapies, with a focus on precision medicine [8][9]

Core Viewpoint - The article discusses the innovative strategies for enhancing CO2-to-lipid bioconversion in microalgae, specifically focusing on the oleaginous Coccomyxa subellipsoidea, to address the challenges of biomass and lipid accumulation for sustainable biodiesel production [1][2]. Summary by Sections Research Findings - The study achieved a biomass concentration of 10.00 g/L, a carbon fixation rate of 1.42 g/L/d, a lipid content of 51.84% dry weight, and a lipid yield of 401.75 mg/L/d under high light intensity (300 μmol/m²/s) [2]. - Chlorophyll fluorescence analysis indicated that high light intensity initially suppressed photosynthetic activity but later activated non-photochemical quenching (NPQ), enhancing the algae's high light tolerance [4]. - Metabolomics analysis showed that high light conditions upregulated protein and free amino acid degradation, facilitating the recycling of nitrogen and carbon resources, which maintained basic cellular metabolism and directed carbon flow towards acetyl-CoA for lipid synthesis [5]. Implications for Biofuel Production - The fatty acid methyl esters produced from this algal strain meet the biodiesel reference standards of China, the USA, and the EU, providing a significant theoretical basis and application case for the development of carbon neutrality and biofuel production technologies [6].

Neurotrophic Keratitis (NK) Market & KB801 Opportunity - The number of patients in the U S with at least one NK claim has increased by over 115% from 31,000 in 2020 to an estimated 68,000 in 2024[9, 10] - In 2023, U S Medicaid and Medicare spent over $540 million on Oxervate, the only FDA-approved therapy for NK[12] - An estimated over 410,000 days of Oxervate therapy were reimbursed in the U S in 2024[12] - KB801 is designed to address the shortcomings of Oxervate, aiming for superior NGF exposure with significantly reduced dosing frequency[11, 21] KB801 Preclinical Data - KB801 transduces primary human corneal epithelial cells in vitro, leading to dose-dependent expression and secretion of mature NGF[25, 26, 29] - In vitro studies confirmed functionality of secreted NGF using a growth factor starved cell proliferation assay[25, 30] - Topical administration of KB801 to wounded murine corneas was well-tolerated and resulted in localized NGF expression[25] - Head-to-head mouse PK studies demonstrated a clear durability advantage with KB801 compared to recombinant NGF, even against intensive recombinant dosing[43, 47] KB801 Clinical Development - The EMERALD-1 study is a Phase 1/2 double-masked, 2:1 randomized, placebo-controlled study in patients with moderate-to-severe NK, with the first patient dosed in July 2025[51, 53, 1] - Krystal is pursuing Platform Technology Designation with the FDA, potentially leading to expedited development of KB801[56, 57]